PUBLISHER: IMARC | PRODUCT CODE: 1722649
PUBLISHER: IMARC | PRODUCT CODE: 1722649
The global smart inhalers market size reached USD 303.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,598.2 Million by 2033, exhibiting a growth rate (CAGR) of 19.25% during 2025-2033.
Smart inhalers are respiratory inhalers that can monitor adherence, send dosage reminders, offer access to readily shareable information via Bluetooth, and record the time, date and location of each dosage administered accurately. They can also help improve compliance with therapy, increase patient involvement and motivation in controlling symptoms, and provide reports about environmental and weather conditions that may affect their chest. Due to the growing prevalence of asthma and chronic obstructive pulmonary diseases (COPD), there is a rise in the demand for smart inhalers across the globe.
Due to a rise in air pollution levels worldwide, there is a significant increase in the number of patients with chronic respiratory diseases (CRDs), lung cancer, chronic bronchitis, and acute lower respiratory infections (ALRI). This represents one of the key factors propelling the growth of the market. Moreover, the efficacy of conventional inhalers can be negatively impacted by incorrect inhaler techniques and poor adherence, which may result in the progression of patients' condition. However, smart inhalers can address the challenges of patients and healthcare professionals in the management of these diseases using digital features designed to connect with mobile applications for monitoring medication schedules and subsequent dosing. Additionally, they can alert patients and clinicians when symptoms require specific action and facilitate a shift to better self-care. This, coupled with recent advances in smart inhaler technology, which allow feedback to users on their inhaler technique and the calculation of the correct level of adherence, is driving the market. Besides this, the increasing awareness about the benefits of using smart inhalers among patients is projected to augment the overall sales and profitability.
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Adherium Limited, AptarGroup Inc., AstraZeneca plc, Boehringer Ingelheim, Cognita Labs, GlaxoSmithKline plc, Novartis AG, OPKO Health Inc., Propeller Health (ResMed), Sensirion AG, Teva Pharmaceutical Industries Ltd. and Vectura Group Limited (Philip Morris International Inc.).